Osteoarthritis, Gout & Joint Pain • ICD-10-CM M25.369
Lower leg/knee instability
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM M25.369 • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Hannah Lindqvist, MD, PhD (NPI #1457952647)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Lower leg/knee instability Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code M25.369 in Arthritis & Joints, Lower leg/knee instability requires topical/targeted anti-inflammatory therapy [Lower leg/knee instability M25.369] so specialists can calibrate treatment intensity against hs-CRP & Erythrocyte in Lower leg/knee instability (M25.369: Sedimentation Rate) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Lower leg/knee instability uses ICD-10 M25.369 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Differential triage of Lower leg/knee instability (M25.369) utilizes topical/targeted anti-inflammatory therapy [Lower leg/knee instability M25.369].
- 4 Top reported side effects / signs: Objective lab/clinical target for Lower leg/knee instability: hs-CRP & Erythrocyte in Lower leg/knee instability (M25.369: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.369)) and Weight-Bearing Joint Radiograph [Lower leg/knee instability M25.369].
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Lower leg/knee instability
What Is Lower leg/knee instability?
Cataloged under federal diagnostic code M25.369 in Arthritis & Joints, Lower leg/knee instability requires topical/targeted anti-inflammatory therapy [Lower leg/knee instability M25.369] so specialists can calibrate treatment intensity against hs-CRP & Erythrocyte in Lower leg/knee instability (M25.369: Sedimentation Rate) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Lower leg/knee instability (ICD-10 M25.369) is driven by monosodium urate or in Lower leg/knee instability (M25.369: calcium pyrophosphate crystal); specialists in Osteoarthritis, Gout & Joint Pain monitor Weight-Bearing Joint Radiograph [Lower leg/knee instability M25.369] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Lower leg/knee instability (M25.369): localized tendon or in Lower leg/knee instability (M25.369: bursa tenderness limiting)
- • Secondary Lower leg/knee instability clinical sign: activity-related deep aching in Lower leg/knee instability (M25.369: joint pain in)
- • Symptom flares in Lower leg/knee instability correlating with hs-CRP & Erythrocyte in Lower leg/knee instability (M25.369: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.369)
- • Functional arthritis & joints impact requiring topical/targeted anti-inflammatory therapy [Lower leg/knee instability M25.369] evaluation (M25.369)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lower leg/knee instability Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M25.369 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Lower leg/knee instability (M25.369: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.369) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Lower leg/knee instability M25.369] | Preserved joint-space width (M25.369) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Lower leg/knee instability (M25.369: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.369) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Lower leg/knee instability
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Amlodipine and Atorvastatin Caduet • RxCUI 597977 | Calcium Channel Blocker | 86% | $1.5140 | $ 69.82 /mo |
| Phenazopyridine Hydrochloride Uqora Maximum Uti Pain Relief, Urinary Pain Relief • RxCUI 1094104 | Over-the-Counter Clinical Monograph | 92% | $0.1748 | $ 15.58 /mo |
| Prazosin Hydrochloride Minipress • RxCUI 312594 | alpha-Adrenergic Blocker | 83% | $0.0823 | $ 8.87 /mo |
| Lumasiran Oxlumo • RxCUI 2467153 | FDA Prescription Therapeutic Agent | 86% | $1.8800 | $ 84.64 /mo |
| Nirsevimab Beyfortus • RxCUI 2642406 | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody | 84% | $1.0900 | $ 52.65 /mo |
| Quinapril Quinapril Generic • RxCUI 312748 | Angiotensin Converting Enzyme Inhibitor | 80% | $2.6900 | $ 117.45 /mo |
| Atenolol and Chlorthalidone Atenolol and Chlorthalidone Generic • RxCUI 197382 | beta-Adrenergic Blocker | 75% | $0.2217 | $ 17.48 /mo |
| Olmesartan Medoxomil-Hydrochlorothiazide Benicar Hct • RxCUI 403853 | Thiazide Diuretic | 85% | $0.2055 | $ 16.82 /mo |
| Metoprolol Succinate Toprol Xl, Kapspargo • RxCUI 866412 | beta-Adrenergic Blocker | 74% | $0.1714 | $ 5.43 /mo |
| Azilsartan Kamedoxomil and Chlorthalidone Edarbyclor • RxCUI 1235144 | Thiazide-like Diuretic | 94% | $8.4940 | $ 185.00 /mo |
| Irbesartan Avapro • RxCUI 200094 | Angiotensin 2 Receptor Blocker | 86% | $0.0800 | $ 8.56 /mo |
| Benazepril Hydrochloride Lotensin • RxCUI 898687 | Angiotensin Converting Enzyme Inhibitor | 75% | $0.0649 | $ 5.79 /mo |
| Felodipine Felopdipine • RxCUI 402695 | Dihydropyridine Calcium Channel Blocker | 91% | $0.1193 | $ 13.33 /mo |
| Carbidopa and Levodopa Carbidopa-Levodopa, Sinemet • RxCUI 197444 | Aromatic Amino Acid Decarboxylation Inhibitor | 85% | $0.1085 | $ 12.89 /mo |
| Atenolol Tenormin • RxCUI 197379 | beta-Adrenergic Blocker | 83% | $0.0211 | $ 5.33 /mo |
| Lisinopril/Hctz Zestoretic • RxCUI 197886 | Thiazide Diuretic | 89% | $0.0188 | $ 5.44 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lower leg/knee instability)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone Replacement Therapy on Lower Urinary Tract: What a 2,029-Participant Study Found In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. European urology • 2016-06-15 • Meta-Analysis | N = 2,029 | 99/100 | PMID 26874809 ↗ |
| New Insights on Effect of testosterone replacement therapy on lower urinary tract: What a 2,453-Participant Study Found The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Journal of evidence-based medicine • 2024-09-15 • Meta-Analysis | N = 2,453 | 99/100 | PMID 39004879 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Lower leg/knee instability Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Lower leg/knee instability community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Lower leg/knee instability.